MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Home・Aktien・Cogent Biosciences Inc

Cogent Biosciences Inc

Geschlossen

15.56 0.91

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

15.14

Max

15.83

Schlüsselkennzahlen
By Trading Economics
Einkommen	-1.5M -74M
Gewinnspanne	-1,582.642
Angestellte	205
EBITDA	1.7M -72M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+37.95% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	10. Nov. 2025

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	541M 2.2B
Vorheriger Eröffnungskurs	14.65
Vorheriger Schlusskurs	15.56

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

4.88 / 5.87 Unterstützung & Widerstand

Cogent Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

8. Okt. 2025, 20:45 UTC

Ergebnisse

Costco Wholesale Sales Climb in September, Early October

8. Okt. 2025, 20:12 UTC

Wichtige Markttreiber

Akquisitionen, Fusionen, Übernahmen

TaskUs Shares Fall After Holders Reject Take-Private Deal

8. Okt. 2025, 16:39 UTC

Wichtige Markttreiber

Mining Shares Rise as Gold Prices Soar

8. Okt. 2025, 23:45 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

8. Okt. 2025, 23:43 UTC

Market Talk

Gold Falls on Possible Profit-Taking -- Market Talk

8. Okt. 2025, 23:18 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics to Finance Acquisition Using Internal Funds

8. Okt. 2025, 23:17 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics to Buy On-Demand Delivery Services Business for US$270.0M

8. Okt. 2025, 23:16 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics to Buy JD.com's On-Demand Delivery Services Business Dajiang and Dasheng

8. Okt. 2025, 21:54 UTC

Market Talk

Ergebnisse

James Hardie Could Beat Annual Earnings Goal -- Market Talk

8. Okt. 2025, 21:30 UTC

Market Talk

Boab Metals Bull Delivers Second Upgrade in a Month -- Market Talk

8. Okt. 2025, 21:26 UTC

Market Talk

Ergebnisse

Transurban's 1Q Traffic Growth Beats Hopes -- Market Talk

8. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Okt. 2025, 19:15 UTC

Market Talk

Geopolitical Risk Supports Gains in Oil Futures -- Market Talk

8. Okt. 2025, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back Ahead of Storage Data -- Market Talk

8. Okt. 2025, 18:47 UTC

Market Talk

Coca-Cola North America Sales Buoy International Weakness -- Market Talk

8. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

TaskUs: Neither Party Will Be Required to Pay Termination Fee as Result of Planned Mutual Decision to Terminate

8. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

TaskUs Will Remain a Publicly Traded Co >TASK

8. Okt. 2025, 18:46 UTC

Akquisitionen, Fusionen, Übernahmen

TaskUs Does Not Plan to Convene Another Special Meeting of Stockholders >TASK

8. Okt. 2025, 18:45 UTC

Akquisitionen, Fusionen, Übernahmen

TaskUs Didn't Receive Votes Necessary to Approve Transaction Agreement With Affil of Blackstone >TASK

8. Okt. 2025, 18:07 UTC

Market Talk

Mexico's Inflation Seen Edging Up in September -- Market Talk

8. Okt. 2025, 16:20 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Energy & Utilities Roundup: Market Talk

8. Okt. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. Okt. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. Okt. 2025, 15:57 UTC

Market Talk

Oil Rises Despite U.S. Crude Stockpiles Build -- Market Talk

8. Okt. 2025, 15:56 UTC

Market Talk

Teck Resources' Chile Mine Issues Appear Transitory -- Market Talk

8. Okt. 2025, 15:53 UTC

Market Talk

Argentine Sovereign Debt Seen as Attractive -- Market Talk

8. Okt. 2025, 15:44 UTC

Akquisitionen, Fusionen, Übernahmen

Staar Surgical: Broadwood's Proposal to Vote Down Merger Could Allow It to Take Control Without Paying Any Premium

8. Okt. 2025, 15:44 UTC

Akquisitionen, Fusionen, Übernahmen

Staar Surgical Board and Management Disagree With Recommendation Issued by Glass Lewis >STAA

8. Okt. 2025, 15:43 UTC

Akquisitionen, Fusionen, Übernahmen

STAAR Surgical Board Reiterates Unanimous Recommendation Holders Vote for Alcon Merger

8. Okt. 2025, 15:42 UTC

Akquisitionen, Fusionen, Übernahmen

Oracle Is a Buy-the-Dip Opportunity, Analyst Says. How the Stock Could Rise 23%. -- Barrons.com

Peer-Vergleich

Kursveränderung

Cogent Biosciences Inc Prognose

Kursziel

By TipRanks

37.95% Vorteil

12-Monats-Prognose

Durchschnitt 21.3 USD 37.95%

Hoch 30 USD

Tief 11 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cogent Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

11 ratings

Buy

Halten

Sell

Basierend auf 11 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Cogent Biosciences Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

4.88 / 5.87Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.